Moonwalk’s technologies bring the most advanced AI prediction of epigenetic targets and the broadest set of epigenetic engineering tools for perturbation. It is the only first end-to-end epigenetic discovery platform capable of profiling the epigenome at the whole genome with single-cell resolution. This positions us well to identify targets related to gene regulation, as well as the best modalities by which to modulate them (e.g. small molecules, oligonucleotide therapies or direct editing strategies).

We utilize large-scale genome-wide profiling and perturbation studies to reveal causal relationships between the epigenome, genome, and gene expression. When applied to disease models, this approach identifies targets (both novel and a better understanding of known target biology) for which suppression or activation can modify pathological gene expression. This enables us and our partners to develop therapies utilizing traditional and editing modalities, informed by the most comprehensive understanding of causal epigenomic biology.